These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 18707724)

  • 1. Predicting prostate cancer risk through incorporation of prostate cancer gene 3.
    Ankerst DP; Groskopf J; Day JR; Blase A; Rittenhouse H; Pollock BH; Tangen C; Parekh D; Leach RJ; Thompson I
    J Urol; 2008 Oct; 180(4):1303-8; discussion 1308. PubMed ID: 18707724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prostate cancer risk calculator from the Prostate Cancer Prevention Trial underestimates the risk of high grade cancer in contemporary referral patients.
    Ngo TC; Turnbull BB; Lavori PW; Presti JC
    J Urol; 2011 Feb; 185(2):483-7. PubMed ID: 21167519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment.
    Tomlins SA; Day JR; Lonigro RJ; Hovelson DH; Siddiqui J; Kunju LP; Dunn RL; Meyer S; Hodge P; Groskopf J; Wei JT; Chinnaiyan AM
    Eur Urol; 2016 Jul; 70(1):45-53. PubMed ID: 25985884
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone.
    Hernandez DJ; Han M; Humphreys EB; Mangold LA; Taneja SS; Childs SJ; Bartsch G; Partin AW
    BJU Int; 2009 Mar; 103(5):609-14. PubMed ID: 19007374
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation in a multiple urology practice cohort of the Prostate Cancer Prevention Trial calculator for predicting prostate cancer detection.
    Eyre SJ; Ankerst DP; Wei JT; Nair PV; Regan MM; Bueti G; Tang J; Rubin MA; Kearney M; Thompson IM; Sanda MG
    J Urol; 2009 Dec; 182(6):2653-8. PubMed ID: 19836788
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective multicentre evaluation of PCA3 and TMPRSS2-ERG gene fusions as diagnostic and prognostic urinary biomarkers for prostate cancer.
    Leyten GH; Hessels D; Jannink SA; Smit FP; de Jong H; Cornel EB; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; van Oort IM; Mulders PF; Hulsbergen-van de Kaa CA; Schalken JA
    Eur Urol; 2014 Mar; 65(3):534-42. PubMed ID: 23201468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External validation of the Prostate Cancer Prevention Trial risk calculator in a screened population.
    Parekh DJ; Ankerst DP; Higgins BA; Hernandez J; Canby-Hagino E; Brand T; Troyer DA; Leach RJ; Thompson IM
    Urology; 2006 Dec; 68(6):1152-5. PubMed ID: 17169636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study.
    Liang Y; Ketchum NS; Louden C; Jimenez-Rios MA; Thompson IM; Camarena-Reynoso HR
    Urol Int; 2012; 89(1):9-16. PubMed ID: 22626812
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiparametric magnetic resonance imaging outperforms the Prostate Cancer Prevention Trial risk calculator in predicting clinically significant prostate cancer.
    Salami SS; Vira MA; Turkbey B; Fakhoury M; Yaskiv O; Villani R; Ben-Levi E; Rastinehad AR
    Cancer; 2014 Sep; 120(18):2876-82. PubMed ID: 24917122
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate Cancer Prevention Trial risk calculator 2.0 for the prediction of low- vs high-grade prostate cancer.
    Ankerst DP; Hoefler J; Bock S; Goodman PJ; Vickers A; Hernandez J; Sokoll LJ; Sanda MG; Wei JT; Leach RJ; Thompson IM
    Urology; 2014 Jun; 83(6):1362-7. PubMed ID: 24862395
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prospective evaluation on the effect of interobserver variability of digital rectal examination on the performance of the Rotterdam Prostate Cancer Risk Calculator.
    Pereira-Azevedo N; Braga I; Verbeek JF; Osório L; Cavadas V; Fraga A; Carrasquinho E; Cardoso de Oliveira E; Nieboer D; Roobol MJ
    Int J Urol; 2017 Dec; 24(12):826-832. PubMed ID: 28901582
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of prostate cancer prevention trial risk calculator in a contemporary cohort screened for prostate cancer and diagnosed by extended prostate biopsy.
    Nguyen CT; Yu C; Moussa A; Kattan MW; Jones JS
    J Urol; 2010 Feb; 183(2):529-33. PubMed ID: 20006887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The impact of prostate volume, number of biopsy cores and American Urological Association symptom score on the sensitivity of cancer detection using the Prostate Cancer Prevention Trial risk calculator.
    Ankerst DP; Till C; Boeck A; Goodman P; Tangen CM; Feng Z; Partin AW; Chan DW; Sokoll L; Kagan J; Wei JT; Thompson IM
    J Urol; 2013 Jul; 190(1):70-6. PubMed ID: 23313212
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development and External Validation of the Korean Prostate Cancer Risk Calculator for High-Grade Prostate Cancer: Comparison with Two Western Risk Calculators in an Asian Cohort.
    Park JY; Yoon S; Park MS; Choi H; Bae JH; Moon DG; Hong SK; Lee SE; Park C; Byun SS
    PLoS One; 2017; 12(1):e0168917. PubMed ID: 28046017
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score.
    Van Neste L; Hendriks RJ; Dijkstra S; Trooskens G; Cornel EB; Jannink SA; de Jong H; Hessels D; Smit FP; Melchers WJ; Leyten GH; de Reijke TM; Vergunst H; Kil P; Knipscheer BC; Hulsbergen-van de Kaa CA; Mulders PF; van Oort IM; Van Criekinge W; Schalken JA
    Eur Urol; 2016 Nov; 70(5):740-748. PubMed ID: 27108162
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incorporation of Urinary Prostate Cancer Antigen 3 and TMPRSS2:ERG into Prostate Cancer Prevention Trial Risk Calculator.
    Ankerst DP; Goros M; Tomlins SA; Patil D; Feng Z; Wei JT; Sanda MG; Gelfond J; Thompson IM; Leach RJ; Liss MA
    Eur Urol Focus; 2019 Jan; 5(1):54-61. PubMed ID: 29422418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The performance of prostate specific antigen for predicting prostate cancer is maintained after a prior negative prostate biopsy.
    Thompson IM; Tangen CM; Ankerst DP; Chi C; Lucia MS; Goodman P; Parnes H; Coltman CA
    J Urol; 2008 Aug; 180(2):544-7. PubMed ID: 18550097
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluating the Prostate Cancer Prevention Trial High Grade Prostate Cancer Risk Calculator in 10 international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Jones JS; Cronin AM; Roobol MJ; Hugosson J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ; Thompson IM
    World J Urol; 2014 Feb; 32(1):185-91. PubMed ID: 22527674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing the prediction of prostate biopsy outcome using the Chinese Prostate Cancer Consortium (CPCC) Risk Calculator and the Asian adapted Rotterdam European Randomized Study of Screening for Prostate Cancer (ERSPC) Risk Calculator in Chinese and European men.
    Chen R; Verbeek JFM; Yang Y; Song Z; Sun Y; Roobol MJ
    World J Urol; 2021 Jan; 39(1):73-80. PubMed ID: 32279141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating the PCPT risk calculator in ten international biopsy cohorts: results from the Prostate Biopsy Collaborative Group.
    Ankerst DP; Boeck A; Freedland SJ; Thompson IM; Cronin AM; Roobol MJ; Hugosson J; Stephen Jones J; Kattan MW; Klein EA; Hamdy F; Neal D; Donovan J; Parekh DJ; Klocker H; Horninger W; Benchikh A; Salama G; Villers A; Moreira DM; Schröder FH; Lilja H; Vickers AJ
    World J Urol; 2012 Apr; 30(2):181-7. PubMed ID: 22210512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.